Imatinib was the first FDA-approved tyrosine-kinase inhibitor. The drug was designed to block the breakpoint cluster region tyrosine kinase (BCR:ABL) produced by the Philadelphia chromosome associated with chronic myelogenous leukemia and acute lymphocytic leukemia. The pharmacokinetics of imatinib demonstrate a mean time to maximum concentration of 2 to 4 hours, with a terminal half-life of 15 hours.40 Imatinib also has shown activity against GI stroma tumors (GIST) that are positive for c-kit (CD117). Numerous drug interactions have been reported for imatinib. CYP450 3A4 inducers, such as rifampicin and St. John's wort, increase the clearance of imatinib.41,42 Ketoconazole, a CYP450 3A4 inhibitor, has been shown to decrease imatinib clearance by almost 30%.43 Imatinib also may increase the exposure of simvastatin, a CYP450 3A4 substrate.44

Stop Headache Drug Free

Stop Headache Drug Free

If you are suffering from headaches, you can make the pain stop just by following some basic but little known principles. Take 15 minutes browsing through this guide and you'll find dozens of tips to gain control in the battle against headache pain.

Get My Free Audio Book

Post a comment